Rep. Cuellar Announces Lower Prescription Drug Costs

Dr. Cuellar Voted to Pass the Inflation Reduction Act (IRA), Which Enabled Negotiations to Lower Costs for Prescription Drugs Under Medicare

Translate to Spanish or other 102 languages!

Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare. Image for illustration purposes
Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare. Image for illustration purposes
- Advertisement -

Washington, DC – Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare.

“I voted to pass the IRA, which has lowered health care and prescription drug costs for Americans. It not only capped the monthly cost of insulin for seniors on Medicare at $35 but also limited out-of-pocket prescription drug costs for seniors,” said Dr. Cuellar, a senior member of the House Appropriations Committee. “Furthermore, due to the IRA, the administration was able to negotiate lower costs for ten of the most expensive prescription drugs under Medicare. This is a historic achievement and will bring needed relief to everyday Americans. I voted for the Inflation Reduction Act to ensure that Americans get the help they need. I will continue to support efforts to reduce health care costs.” 

The ten drugs negotiated down include Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog/Fiasp.

- Advertisement -

Through the IRA, more than 100,000 Texans on Medicare are saving on average $441 per year through the insulin price cap alone.  It caps insulin costs at $35 per month for those on Medicare and limits out-of-pocket prescription drug costs to $2,000 per year.

1,323,430 Texans will save $400 per year on average through the IRA’s $2,000 out-of-pocket cap, which will begin in 2025.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves Expanded Use of Kidney Cancer Treatment Rooted in UTSW Discovery

Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved by the Food and Drug Administration to treat some patients with earlier stage kidney cancers in combination with an immunotherapy drug. This move marks the latest expansion of belzutifan’s indications after it was originally approved in 2021.

STHS to Raise Awareness of PTSD in Latest South Texas Healthy Living Episode, June 28th

If you’re experiencing intrusive, distressing memories or feeling constantly on edge following a traumatic event, you may be living with post-traumatic stress disorder (PTSD) and you’re not alone. 

STHS Highlights Life-Saving Habits for Men

While men face unique health challenges, experts say routine preventive care, healthy lifestyle habits and early intervention can significantly improve health outcomes and overall quality of life.

Health Experts Issue Comprehensive Roadmap to Reduce Kids’ Sugar Intake

American children consume more than double the recommended amount of added sugars each day, contributing to rising rates of childhood obesity, type 2 diabetes, and other chronic health conditions.
- Advertisement -